$RPRX (Royalty Pharma plc) — investor discussion on X

Five-factor rating: Buy (sector percentile 78.0%)

Graded daily on value B+, growth C, profitability A-, momentum B, revisions A-. Sector-relative, identical for every user.

Most active credible voices on $RPRX

@stockmktnewz (Evan) — 13 mentions · 1.1M followers
@drstoxx (Dr. Stoxx) — 2 mentions · 22.5K followers
@ewhispers (Earnings Whispers) — 2 mentions · 570.9K followers

Recent headlines featuring $RPRX

2026-09-08: Novartis del-desiran fails Phase 3 as NVS falls 10% after a week of setbacks

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $RPRX are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$RPRX (Royalty Pharma plc) — investor discussion on X

Five-factor rating: Buy (sector percentile 78.0%)

Graded daily on value B+, growth C, profitability A-, momentum B, revisions A-. Sector-relative, identical for every user.

Most active credible voices on $RPRX

@stockmktnewz (Evan) — 13 mentions · 1.1M followers
@drstoxx (Dr. Stoxx) — 2 mentions · 22.5K followers
@ewhispers (Earnings Whispers) — 2 mentions · 570.9K followers

Recent headlines featuring $RPRX

2026-09-08: Novartis del-desiran fails Phase 3 as NVS falls 10% after a week of setbacks

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $RPRX are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$RPRXRoyalty Pharma plc · Medical - Pharmaceuticals · $25.5B

$57.62

-0.0%

Event thread

Key events, in time order

4 items

2026-08-15AnalystBull
Pat Dorsey's Fund Adds to Royalty Pharma Stake in Q2
Dorsey Asset Management increased its position in RPRX, signaling institutional conviction
D1 +1.5% · +5d +3.2%
2026-08-05EarningsBull
Royalty Pharma Q2 Earnings Beat, FY2026 Guidance Raised
Q2 EPS $1.32 beat estimates; FY portfolio receipts guidance raised to $3.4B
D1 +0.5% · +5d +2.5%
2 waves of this story
- 2026-08-05 Portfolio receipts up 6% to $773M, royalty receipts up 14%, full-year guidance raised
- 2026-08-05 Q2 EPS $1.32 beat estimates; FY portfolio receipts guidance raised to $3.4B

2 earlier events

2026-08-05Earnings
Earnings report
D1 +0.5% · +5d +2.5%
2026-08-058-K filing
8-K: Item 2.02, Item 9.01
D1 +0.5% · +5d +2.5%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

4 items

2026-08-15AnalystBull
Pat Dorsey's Fund Adds to Royalty Pharma Stake in Q2
Dorsey Asset Management increased its position in RPRX, signaling institutional conviction
D1 +1.5% · +5d +3.2%
2026-08-05EarningsBull
Royalty Pharma Q2 Earnings Beat, FY2026 Guidance Raised
Q2 EPS $1.32 beat estimates; FY portfolio receipts guidance raised to $3.4B
D1 +0.5% · +5d +2.5%
2 waves of this story
- 2026-08-05 Portfolio receipts up 6% to $773M, royalty receipts up 14%, full-year guidance raised
- 2026-08-05 Q2 EPS $1.32 beat estimates; FY portfolio receipts guidance raised to $3.4B
2026-08-05Earnings
Earnings report
D1 +0.5% · +5d +2.5%
2026-08-058-K filing
8-K: Item 2.02, Item 9.01
D1 +0.5% · +5d +2.5%

$RPRX (Royalty Pharma plc) — investor discussion on X

Five-factor rating: Buy (sector percentile 78.0%)

Most active credible voices on $RPRX

Recent headlines featuring $RPRX

$RPRX (Royalty Pharma plc) — investor discussion on X

Five-factor rating: Buy (sector percentile 78.0%)

Most active credible voices on $RPRX

Recent headlines featuring $RPRX

Pat Dorsey's Fund Adds to Royalty Pharma Stake in Q2

Royalty Pharma Q2 Earnings Beat, FY2026 Guidance Raised

Earnings report

8-K: Item 2.02, Item 9.01

Bull vs bear

Discussion

Pat Dorsey's Fund Adds to Royalty Pharma Stake in Q2

Royalty Pharma Q2 Earnings Beat, FY2026 Guidance Raised

Earnings report

8-K: Item 2.02, Item 9.01